The 2020 guidelines from the European Society of Cardiology Cardio-Oncology Study Group and International Cardio-Oncology Society suggest utilizing baseline characteristics including history of prior cardiovascular disease, biomarkers such as troponin and NT-proBNP, demographics, cardiovascular risk factors, prior chemotherapy treatment, and lifestyle factors for the purposes of anthracycline-induced cardiotoxicity risk stratification [21]. Here, NPPB is linked to cardiovascular disorder.